Creative Medical Technology Holdings, Inc. develops regenerative medicine and immune-cell therapies as a clinical-stage biotechnology company trading under CELZ. Company news centers on CELZ-201, or olastrocel, an allogeneic/perinatal tissue-derived cell therapy evaluated in the FDA-cleared ADAPT trial for chronic lower back pain associated with degenerative disc disease, and on platform extensions such as Ultrasome for knee osteoarthritis.
Recurring updates also cover WHO International Nonproprietary Name activity for cell-therapy assets, CELZ-101 Treg immunotherapy work, and BioDefense Inc., a wholly owned subsidiary focused on burn pit exposure research using iPSC technology, AI-enabled molecular modeling, and regenerative countermeasure development.
Creative Medical Technology Holdings (OTC-CELZ) has provided an update on its corporate activities, showcasing growth in its stem cell programs. The CaverStem program is expanding, with record kit orders and new practitioners in Houston and Scottsdale. The FemCelz program is gaining traction, and marketing efforts are set to increase. A patent approval for OvaStem highlights progress in treating ovarian failure. The TregSpine and AmnioStem programs are advancing, with an IND application expected in Q4 2020. Despite challenges, the company remains optimistic about its growth.
Creative Medical Technology Holdings announced a Notice of Allowance for its patent on using T regulatory cells to enhance blood circulation for lower back pain treatment. This patent is vital as many patients suffer from poor circulation, contributing to pain. The company also holds a prior patent for stem cell therapy for lower back pain. The CEO highlighted the growing market for such therapies, citing a $1 billion deal in the sector. They are focused on expanding their intellectual property and welcome collaborations within the biotechnology community.
Creative Medical Technology Holdings (CELZ) announced new findings showing that AmnioStem® stem cells can effectively suppress stroke-related pathological molecules. These cells block harmful cytokine production and reprogram macrophages from a damaging to a reparative role, offering a potential advantage over other treatments. The company plans to publish this data and include it in its FDA IND submission. This positions the firm favorably, aiming for FDA clearance and stronger intellectual property protection.